<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="./css/bootstrap.min.css">
    <link rel="stylesheet" href="./css/all.min.css">
    <link rel="stylesheet" href="./css/fontawesome.min.css">
    <link rel="stylesheet" href="./css/style.css">
    <title>Diabetes 360 eMagazine</title>
</head>
<body>


    <div class="container">
    <div class="main">
        <div class="left">
            <a href="./page-11.html"><img src="./img/prev.png" alt="previous"></a>
        </div>
        <div class="right">
            <a href="./page-13.html"><img src="./img/next.png" alt="next"></a>
        </div>
        
        <header class="pages-header-footer pages-h-f-white">
            <div class="row align-items-center m-0">
                <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                <div class="col-7 align-content-center"><div class="dark-line"></div></div>
                <div class="col-2"><img src="img/sanofi-logo-black.png" alt=""></div>
            </div>
        </header>
        <div class="article-head">
            <h1 class="headline"><span class="bold">iGlarLixi versus Premixed Insulin Initiation in Adults
                with Type 2 Diabetes Advancing from Basal Insulin
                Therapy:</span>
                The SoliComplex Real-world Study</h1>
                <hr>
            <div class="subheader">
                <p class="primary-col">Source: Lajara R, Heller C, Pantalone KM, Lew E, Li X, Dex T, Kilpatrick CR. iGlarLixi versus premixed insulin initiation in adults with type
                    2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study. Diabetes Obes Metab. 2023 May;25(5):1249-1260</p>
            </div>
        </div>
        <article>
            <div class="row">
                <div class="col-lg-6 col-sm-12">
                    <div class="feature-img">
                        <img src="./img/magazine-edit-13-3-22.jpg" alt="feature-img">
                    </div>
                    <p>
                        Premixed insulin is typically taken twice day, though
additional injections may be added based on the
needs of each patient’s treatment. Premixed insulin is
frequently used to moderate increases in postprandial
glucose excursions in patients who have inadequate
control following oral or basal insulin therapy. It is
especially useful for patients who have regular eating
patterns and who need to streamline their treatment.
                    </p>
                    <p>iGlarLixi, a fixed-ratio combination therapy comprising
                        insulin glargine 100 U/ml and the glucagon-like
                        peptide-1 receptor agonist (GLP-1 RA) lixisenatide, is a
                        once-daily alternative to premixed insulin. Lajara et al.,
                        reported the results of a real-world observational study
                        conducted to compare treatment persistence in adults
                        with T2D suboptimally controlled with basal insulin
                        who initiated therapy with either iGlarLixi or a premixed
                        insulin regimen. Treatment adherence, change in HbA<sub>1c</sub>,
                        hypoglycemia events, and all-cause, diabetes-related
                        and hypoglycemia-related HRU and healthcare costs at
                        12 months were also assessed as secondary endpoints.
                        Subgroup analyses assessed outcomes in people aged
                        65 years or older, and in those who had a baseline HbA<sub>1c</sub>
                        of 9% or higher.
                    </p>
                    <p>
                        Data from adults (age ≥ 18 years) with T2D who had
                    </p>
                </div>
    
                <div class="col-lg-6 col-sm-12">
                    <p>
                        previously received basal insulin and newly initiated
iGlar-Lixi or premixed insulin were used for this
retrospective real-world analysis. Using a greedy nearest
neighbor matching algorithm, cohorts were propensityscore
matched based on baseline characteristics, and
outcomes were evaluated after 12 months. For people
65 years of age or older and those whose baseline HbA<sub>1c</sub> was 9% or higher, subgroup analyses were conducted.
                    </p>
                    <p>
                        Treatment persistence across the population was
the main outcome. Treatment adherence, healthcare
resource use (HRU), costs, hypoglycemia events, and
change in HbA<sub>1c</sub> from baseline were secondary endpoints.
There were 834 participants in each cohort. Treatment
persistence was statistically significantly higher for
iGlarLixi than premixed insulin in the general population
at 12 months: 42.5% versus 39.1%; hazard ratio 0.88; 95%
confidence interval 0.778-0.998; p=.0465. Adherence and
HbA<sub>1c</sub> reduction were comparable between groups, but
iGlarLixi had numerically lower rates of hypoglycemia
events, HRU, and costs. Results in the subgroup of
people 65 years of age or older as well as those with an
HbA<sub>1c</sub> of 9% or higher were comparable to those for the
general population.
                    </p>
                    
                    <div class="purple-quote primary-bg">
                        <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                        <h3>Conclusion</h3>
                        <p>
                            The results of this retrospective, realworld
observation study in adults with T2D
suboptimally controlled on basal insulin
showed that once-daily iGlarLixi is an effective
treatment alternative to premixed insulin,
with significantly higher although probably
clinically similar treatment persistence,
similar adherence and HbA<sub>1c</sub> reduction, and
numerically lower hypoglycemia events, HRU
and costs. As the results from the overall
population were replicated in the subgroup
aged 65 years or older, as well as those with
a baseline HbA<sub>1c</sub> of 9% or higher, iGlarLixi can
also be considered an appropriate treatment
simplification option for older adults with T2D
that is suboptimally controlled on basal insulin,
who need a regimen with a low associated risk
of hypoglycemia and improved simplicity with
once-daily administration.
                        </p>
                    </div>
                    
                </div>
            </div>
            
            <div class="article-footer">
                <div class="row">
                    <div class="col-lg-6 col-sm-12">
                        <div class="ref-rating">
                            <p>
                                T2D, type 2 diabetes; HbA<sub>1c</sub>, hemoglobin A1c; HRU, healthcare resource utilization.
                            </p>                    
                        </div>
                        <div class="rating">
                            <p>How do you rate this article?</p>
                            <div class="row px-4">
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                            </div>
                            <div class="rating-bar">
                                <img src="./img/rating-1-5.png" alt="">
                            </div>  
                        </div>
                    </div>
                </div>
            </div>
        </article>
        </div>
        <footer class="footer">
            <div class="pages-header-footer">
                <div class="row">
                    <div class="col-1">
                        <div class="pagination">
                            <p>12</p>
                        </div>
                    </div>
                    <div class="col-8 align-content-center p-0">
                        <div class="dark-line"></div>
                    </div>
                    <div class="col-3 d-flex justify-content-center align-items-center">
                        <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                    </div>
                </div>
            </div>
        
    </footer>

        </div>

    </div>    
    </div>


    <script src="./js/bootstrap.bundle.min.js"></script>
    </body>
</html>